支气管镜活检综合生物标志物检测的安全性与样本充分性:美国支气管病与介入肺脏病学会及国际肺癌研究协会临床实践指南
该指南由美国支气管病与介入肺脏病学会和国际肺癌研究协会组建多学科专家组,针对四种患者、干预、比较和结局问题,采用改良德尔菲技术形成推荐,涉及对确诊或疑似肺癌患者进行微创胸部干预时综合生物标志物检测的安全性与样本充分性。
要点
- 指南聚焦肺癌微创胸部活检技术用于综合生物标志物检测的安全性与样本充分性。
- 专家组由12个国家22家医院的24名专家组成,采用改良德尔菲技术形成推荐。
- 推荐适用于确诊或疑似肺癌、需综合生物标志物检测以指导标准治疗或临床试验的患者。
核心结论
- 指南针对肺癌微创胸部活检技术用于综合生物标志物检测的安全性与样本充分性提供具体推荐。
研究设计与样本
- 美国支气管病与介入肺脏病学会和国际肺癌研究协会组建多学科专家组,采用改良德尔菲技术制定临床实践指南。
- 专家组共24名专家,包括18名肺科医生、2名放射科医生、1名病理科医生和3名胸外科医生,来自12个国家的22家医院。
主要发现
- 专家组针对四种患者、干预、比较和结局问题进行了回答,涉及常用胸腔内活检技术用于综合生物标志物检测的安全性与充分性。
关键数值与推荐
- 指南就确诊或疑似肺癌患者需综合生物标志物检测以指导标准治疗或临床试验时,微创胸部干预的安全性与样本充分性提供具体推荐。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Linear endobronchial ultrasound-guided sampling of accessible mediastinal lesions is well established as a first-choice modality for lung cancer mediastinal staging. Parenchymal lung lesions, however, are routinely accessed by either a percutaneous (computed tomography guided) or a bronchoscopic approach. Direct comparisons between the percutaneous approach and bronchoscopy, endobronchial ultrasound, or mediastinoscopy are sparse in regard to diagnostic accuracy, and it remains unknown which sampling technique is the safest and offers the most adequate material for comprehensive biomarker testing. This guideline addresses new evidence and aims to answer these questions relevant to contemporary lung cancer clinical practice. A multidisciplinary expert panel from the American Association of Bronchology and Interventional Pulmonology and the Early Detection and Screening Committee of the International Association for the Study of Lung Cancer was convened to address four Patient, Intervention, Comparison, and Outcome questions pertaining to the safety and adequacy of comprehensive biomarker testing for frequently used intrathoracic biopsy techniques. The panel included 24 experts in thoracic procedures, including 18 pulmonologists, two radiologists, one pathologist, and three thoracic surgeons from 22 hospitals across 12 countries. All panel members participated in the development of the final recommendations using a modified Delphi technique. Specific recommendations are provided on safety and adequacy of minimally invasive thoracic interventions on patients with confirmed or suspected lung cancer for which comprehensive biomarker testing is needed for standard of care or clinical trial participation.
引用
- Chaddha U, Agrawal A, Ghori U, et al. Safety and Sample Adequacy for Comprehensive Biomarker Testing of Bronchoscopic Biopsies: An American Association of Bronchology and Interventional Pulmonology and International Association for the Study of Lung Cancer Clinical Practice Guideline. J Thorac Oncol. 2025. PMID: 40419141. doi:10.1016/j.jtho.2025.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。